ZaBeCor Pharmaceuticals of Bala Cynwyd said today that it formed a biotechnology subsidiary to develop molecular technologies for treatment of cancers in the blood and lymphatic system.
The new unit, Biothorpe Pharmaceuticals, will focus on attacking a substance called Syk kinase, which studies have shown is required for the proliferation of malignant cells in several cancers, ZaBeCor said. Biothorpe's work will be targeted at three types of cancer: acute myelogenous leukemia, B-cell lymphoma and chronic lymphocytic leukemia.
ZaBeCor, founded in 2002, will continue to concentrate on developing drugs for asthma, allergies and other inflammatory disorders. Its technology is licensed from the University of Pennsylvania.